View in EDS PDF Full Text

Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group.

Saved in:
Bibliographic Details
Title: Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group.
Authors: Højris I (AUTHOR), Overgaard M (AUTHOR), Christensen JJ (AUTHOR), Overgaard J (AUTHOR), Danish Breast Cancer Cooperative Group (CORPORATE AUTHOR), Højris, I (AUTHOR), Overgaard, M (AUTHOR), Christensen, J J (AUTHOR), Overgaard, J (AUTHOR)
Source: Lancet. 10/23/1999, Vol. 354 Issue 9188, p1425-1430. 6p.
Abstract: Background: Radiotherapy in addition to systemic treatment after mastectomy prolongs survival in high-risk breast-cancer patients. However, adjuvant radiotherapy has a potential association with ischaemic heart disease. We assessed morbidity and mortality from ischaemic heart disease in patients treated with postmastectomy radiotherapy.Methods: Between 1982 and 1990, we randomly assigned 3083 women at high risk of breast cancer, after mastectomy, adjuvant systemic treatment with (n=1538) or without (n=1545) radiotherapy. An anterior photon field was used against the periclavicular region and the axilla. The chest wall was treated through two anterior shaped electron fields, one including the internal mammary nodes. The intended dose was 48-50 Gy in 22-25 fractions, at four to five fractions per week. We obtained information on morbidity and mortality of ischaemic heart disease over a median of 10 years. Analysis was by intention to treat.Findings: More women in the no-radiotherapy group than in the radiotherapy group died of breast cancer (799 [52.5%] vs 674 [44.2%]), whereas similar proportions of each group died from ischaemic heart disease (13 [0.9%] vs 12 [0.8%]). The relative hazard of morbidity from ischaemic heart disease among patients in the radiotherapy compared with the no-radiotherapy group was 0.86 (95% CI 0.6-1.3), and that for death from ischaemic heart disease was 0.84 (0.4-1.8). The hazard rate of morbidity from ischaemic heart disease in the radiotherapy group compared with the no-radiotherapy group did not increase with time from treatment.Interpretation: Postmastectomy radiotherapy with this regimen does not increase the actuarial risk of ischaemic heart disease after 12 years. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 107088718
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Højris+I%22">Højris I</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Overgaard+M%22">Overgaard M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Christensen+JJ%22">Christensen JJ</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Overgaard+J%22">Overgaard J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Danish+Breast+Cancer+Cooperative+Group%22">Danish Breast Cancer Cooperative Group</searchLink> (CORPORATE AUTHOR)<br /><searchLink fieldCode="AR" term="%22Højris%2C+I%22">Højris, I</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Overgaard%2C+M%22">Overgaard, M</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Christensen%2C+J+J%22">Christensen, J J</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Overgaard%2C+J%22">Overgaard, J</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 10/23/1999, Vol. 354 Issue 9188, p1425-1430. 6p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Radiotherapy in addition to systemic treatment after mastectomy prolongs survival in high-risk breast-cancer patients. However, adjuvant radiotherapy has a potential association with ischaemic heart disease. We assessed morbidity and mortality from ischaemic heart disease in patients treated with postmastectomy radiotherapy.<bold>Methods: </bold>Between 1982 and 1990, we randomly assigned 3083 women at high risk of breast cancer, after mastectomy, adjuvant systemic treatment with (n=1538) or without (n=1545) radiotherapy. An anterior photon field was used against the periclavicular region and the axilla. The chest wall was treated through two anterior shaped electron fields, one including the internal mammary nodes. The intended dose was 48-50 Gy in 22-25 fractions, at four to five fractions per week. We obtained information on morbidity and mortality of ischaemic heart disease over a median of 10 years. Analysis was by intention to treat.<bold>Findings: </bold>More women in the no-radiotherapy group than in the radiotherapy group died of breast cancer (799 [52.5%] vs 674 [44.2%]), whereas similar proportions of each group died from ischaemic heart disease (13 [0.9%] vs 12 [0.8%]). The relative hazard of morbidity from ischaemic heart disease among patients in the radiotherapy compared with the no-radiotherapy group was 0.86 (95% CI 0.6-1.3), and that for death from ischaemic heart disease was 0.84 (0.4-1.8). The hazard rate of morbidity from ischaemic heart disease in the radiotherapy group compared with the no-radiotherapy group did not increase with time from treatment.<bold>Interpretation: </bold>Postmastectomy radiotherapy with this regimen does not increase the actuarial risk of ischaemic heart disease after 12 years. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=107088718
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/s0140-6736(99)02245-x
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 6
        StartPage: 1425
    Titles:
      – TitleFull: Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Højris I
      – PersonEntity:
          Name:
            NameFull: Overgaard M
      – PersonEntity:
          Name:
            NameFull: Christensen JJ
      – PersonEntity:
          Name:
            NameFull: Overgaard J
      – PersonEntity:
          Name:
            NameFull: Danish Breast Cancer Cooperative Group
      – PersonEntity:
          Name:
            NameFull: Højris, I
      – PersonEntity:
          Name:
            NameFull: Overgaard, M
      – PersonEntity:
          Name:
            NameFull: Christensen, J J
      – PersonEntity:
          Name:
            NameFull: Overgaard, J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 23
              M: 10
              Text: 10/23/1999
              Type: published
              Y: 1999
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 354
            – Type: issue
              Value: 9188
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1